Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer

Pernelle Lavaud; Clément Dumont; Constance Thibault; Laurence Albiges; Giulia Baciarello; Emeline Colomba; Ronan Flippot; Alina Fuerea; Yohann Loriot; Karim Fizazi

doi:10.1177/1758835920978134

Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer

Ther Adv Med Oncol. 2020 Dec 23:12:1758835920978134. doi: 10.1177/1758835920978134. eCollection 2020.

Affiliations

¹ Department of Cancer Medicine, Gustave Roussy Cancer Campus, University of Paris Saclay, Villejuif, France.
² Department of Cancer Medicine, Hôpital Saint Louis, Paris, France.
³ Department of Medical Oncology, Hôpital Européen Georges-Pompidou, Paris, France.
⁴ Department of Cancer Medicine, University of Paris Saclay, Gustave Roussy, 114 Rue Edouard Vaillant, Villejuif, 94805, France.

Abstract

Until recently, continuing androgen deprivation therapy (ADT) and closely monitoring patients until evolution towards metastatic castration-resistant prostate cancer (CRPC) were recommended in men with non-metastatic CRPC (nmCRPC). Because delaying the development of metastases and symptoms in these patients is a major issue, several trials have investigated next-generation androgen receptor (AR) axis inhibitors such as apalutamide, darolutamide, and enzalutamide in this setting. This review summarizes the recent advances in the management of nmCRPC, highlighting the favourable impact of next-generation AR inhibitors on metastases-free survival, overall survival and other clinically meaningful endpoints.

Keywords: apalutamide; castration resistance; darolutamide; enzalutamide; next generation androgen receptor inhibitors; non-metastatic setting; prostate cancer.

Publication types

Review